FDA declines to grant EUA for antidepressant to treat Covid-19
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.

The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
The grant will support two trials of ebselen in 120 adult subjects with moderate or severe Covid-19.
The approval is based on findings from two Phase III clinical trials, ACTT-2 and COV-BARRIER.
This alliance is the third academic-industry partnership of API this year to develop therapies against viral variants.